From 20 July to 23 September 2022, the European Directorate for the Quality of Medicines & HealthCare (EDQM) is seeking the opinions of stakeholders on its draft guidelines for medication review. This consultation targets international organisations active in public health and social matters, relevant authorities in member states, healthcare professionals, patients and academia, and is a valuable opportunity for stakeholders to express their views and for the EDQM to receive input for the finalisation of the draft guidelines for medication review.
Medication review represents a key step in the pharmaceutical care process, as described in the Council of Europe Resolution CM/Res(2020)3 on the implementation of pharmaceutical care for the benefit of patients and health services, adopted in March 2020. The draft guidelines are therefore a major step in supporting the implementation of this resolution and in promoting the rational and safe use of medicines.
The draft guidelines focus primarily on the process of conducting a medication review, including the identification and prioritisation of patients who could benefit from the process and the recommended frequency of medication reviews, how to collect and store related data, and the required professional training. They also foster a common understanding of what a medication review is by promoting the harmonisation of terminology and definitions used in the process. In addition, the draft guidelines provide insight on how to support the development of this service and to facilitate its implementation at European level.
For any enquiries related to the consultation process or the draft guidelines for medication review, please contact the EDQM at [email protected].